Safety and tolerability of onabotulinumtoxinA in the treatment of upper facial lines from global registration studies in 5298 participants: A meta-analysisCapsule Summary

• Egile Nagusiak: Mitchell F. Brin, MD (Egilea), Koen De Boulle, MD (Egilea), Steven Liew, MBBS (Egilea), Alastair Carruthers, MD (Egilea), Jean Carruthers, MD (Egilea), Alexander Rivkin, MD (Egilea), Yan Wu, MD, PhD (Egilea), Makoto Kawashima, MD (Egilea), Irina Yushmanova, MD (Egilea), Terry I. Boodhoo, MS (Egilea), Elisabeth Lee, MPH (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2024-03-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Since its discovery as a facial aesthetic treatment >30 years ago, onabotulinumtoxinA has received worldwide approval for dynamic upper facial line treatment. Objective: Meta-analysis examining the safety of onabotulinumtoxinA for treatment of glabellar lines (GL), crow's feet li...